Alnylam gets NICE backing for porphyria therapy GivlaariUK cost-effectiveness watchdog NICE is set to recommend NHS use of Alnylam’s gene-silencing therapy Givlaari in England and Share XAlnylam gets NICE backing for porphyria therapy Givlaarihttps://pharmaphorum.com/news/alnylam-gets-nice-backing-for-porphyria-therapy-givlaari/
FDA approves Alnylam’s second RNAi drug – with $442K annual price tagAlnylam has had a second RNA interference (RNAi) drug approved by the FDA, to treat the ultra-rare disease Share XFDA approves Alnylam’s second RNAi drug – with $442K annual price taghttps://pharmaphorum.com/news/fda-approved-alnylams-second-rnai-drug/
Alnylam to file gene-silencing porphyria drugAlnylam is to file its givosiran with regulators to treat a form of the blood disease porphyria, applying Share XAlnylam to file gene-silencing porphyria drughttps://pharmaphorum.com/news/alnylam-to-file-gene-silencing-porphyria-drug/
